Neoadjuvant nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA4) prior to surgical resection of Stage I/II NSCLC results in complete pathologic responses in as many as 38% of patients6. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.